Shenzhen Edge Medical publishes 2025 annual report

PUBT·04/28/2026 14:37:25

Listen to the news

Shenzhen Edge Medical annual report for 2025 flagged a step-up in commercialization, led by wider deployment of its endoscopic surgical robot systems in China and overseas.
Overseas expansion accelerated, with MP1000 cleared in 22 jurisdictions covering 55 countries and regions; SP1000 secured registrations in 35 countries and regions.
Regulatory progress broadened product lineup, including China registration for CP1000 bronchoscope robot in January 2025; EU CE marking for MP1000 in March 2025.
Clinical adoption scaled, with more than 14,000 robot-assisted cases completed in China by Dec. 31, 2025; more than 500 telesurgery cases recorded with a 100% success rate.
Manufacturing capacity in Shenzhen rose to more than 100 units a year in 2025, supporting faster deliveries and expanding installed base.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shenzhen Edge Medical Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260428-12131318), on April 28, 2026, and is solely responsible for the information contained therein.

FAQ

Fee Schedule Open Account Deposit & Withdrawal Trading

Terms & Conditions

Client Agreement Privacy Policy Data Disclaimer Security Tips

About Webull

About us Webull Promotions Contact information Announcements

Contact Number :+852 3852 8500

Monday 7:00 AM - Saturday 9:00 AM (HKT)

Service Email :service@webull.hk

Online Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)

Business Cooperation :marketinghk@webull.hk

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.

Language

English